Eloxx Pharmaceuticals, Inc.
Cash Flow Statement
| Line Item | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-21.2M | $-9.8M | $-6.4M | $-9.2M | $-6.1M | $-5.1M | $-7.3M | $-13.4M |
| Depreciation & Amortization | $44.1K | $93.4K | $177.1K | $349.7K | $293.6K | $258.0K | $143.3K | $126.6K |
| Depreciation | $39.0K | $8.0K | $5.0K | $18.3K | $2.6K | $2.4K | $2.8K | $2.5K |
| Amortization | — | — | $25.0K | $331.4K | $291.0K | $255.6K | $140.5K | $124.0K |
| Stock-Based Compensation | $101.0K | $78.0K | $92.0K | $1.3M | $724.7K | $766.0K | $750.4K | $386.6K |
| Net Cash from Operating Activities | $-15.9M | $-8.8M | $-5.7M | $-4.9M | $-3.9M | $-4.4M | $-5.4M | $-4.7M |
| Investing Activities | ||||||||
| Capital Expenditures | $237.0K | $36.0K | $10.0K | $3.2K | $1.3K | $4.5K | $2.0K | $1.1K |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | $-114.0K | $-36.0K | $1.5M | $646.9K | $-529.0K | $-450.5K | $-686.4K | $241.0K |
| Financing Activities | ||||||||
| Dividends Paid | $0 | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | $38.0M | $9.7M | $3.9M | $8.7M | $4.0M | $3.2M | $1.7M | $12.1M |
| Net Change in Cash | $21.8M | $842.0K | $-367.0K | $4.5M | $-399.0K | $-1.6M | $-4.4M | $7.6M |
| Free Cash Flow | $-16.2M | $-8.9M | $-5.7M | $-4.9M | $-3.9M | $-4.4M | $-5.4M | $-4.7M |